STaR study: Single-tablet regimen (STR) of Rilpivirine/Emtricitabine/Tenofovir DF demonstrates significant difference to Efavirenz/Emtricitabine/Tenofovir DF in subjects with a baseline HIV-1 RNA ≤ 100,000 copies/mL through week 96

被引：0

作者：

Wilkins, E. ^{[1
]}

Moyle, G. ^{[2
]}

Orkin, C. ^{[3
]}

Fisher, M. ^{[4
]}

Johnson, M. ^{[5
]}

Arribas, J. ^{[6
]}

Van Lunzen, J. ^{[7
]}

Garner, W. ^{[8
]}

Porter, D. ^{[8
]}

Bosse, M. ^{[8
]}

Scharen-Guivel, V. ^{[8
]}

Reilly, G. ^{[8
]}

Robinson, C. ^{[8
]}

Smith, A. ^{[8
]}

机构：

[1] North Manchester Gen Hosp, Manchester, Lancs, England

[2] Chelsea & Westminster Hosp, London, England

[3] Barts Hlth, London, England

[4] Brighton & Sussex Univ Hosp, Brighton, E Sussex, England

[5] Royal Free London NHS Fdn Trust, London, England

[6] Hosp La Paz, Madrid, Spain

[7] Univ Med Ctr, Hamburg, Germany

[8] Gilead Sci Inc, Foster City, CA 94404 USA

来源：

HIV MEDICINE | 2014年 / 15卷

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：115 / 116

页数：2

共 42 条

[1] Week 96 analyses of emergent drug resistance from the STaR Study: rilpivirine/emtricitabine/tenofovir DF vs. efavirenz/emtricitabine/tenofovir DF single-tablet regimens
Porter, D. P.
Kulkarni, R.
Fralich, T.
Miller, M. D.
White, K. L.
ANTIVIRAL THERAPY, 2014, 19 : A123 - A123
[2] Primary and secondary analyses of emergent drug resistance through week 48 from the STaR Study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF single-tablet regimens
Porter, D. P.
Kulkarni, R.
Fralich, T.
Miller, M. D.
White, K. L.
ANTIVIRAL THERAPY, 2013, 18 : A38 - A38
[3] STaR study: single-tablet regimen rilpivirine/emtricitabine/tenofovir DF maintains non-inferiority to efavirenz/emtricitabine/tenofovir DF and has minimal impact on fasting lipids in ART-naive adults through week 96
Cohen, C.
Wohl, D.
Arribas, J. R.
Henry, K.
van Lunzen, J.
Bloch, M.
Towner, W.
Wilkins, E.
Ebrahimi, R.
Porter, D.
De-Oertel, S.
Fralich, T.
Melbourne, K.
ANTIVIRAL THERAPY, 2013, 18 : A7 - A7
[4] 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects
Porter, Danielle P.
Kulkarni, Rima
Fralich, Todd
Miller, Michael D.
White, Kirsten L.
HIV CLINICAL TRIALS, 2015, 16 (01): : 30 - 38
[5] STAR Study: single tablet regimen emtricitabine/rilpivirine/tenofovir DF is non-inferior to efavirenz/emtricitabine/tenofovir DF in ART-na ve adults
Cohen, C.
Wohl, D.
Arribas, J.
Henry, K.
Van Lunzen, J.
Bloch, M.
Towner, W.
Wilkins, E.
Wang, H.
White, K.
Porter, Poulin D.
Guyer, B.
Fralich, T.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 24 - 24
[6] A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results
Wohl, David A.
Cohen, Calvin
Gallant, Joel E.
Mills, Anthony
Sax, Paul E.
DeJesus, Edwin
Zolopa, Andrew
Liu, Hui C.
Plummer, Andrew
White, Kirsten L.
Cheng, Andrew K.
Rhee, Martin S.
Szwarcberg, Javier
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 65 (03) : E118 - E121
[7] Characterization of HIV-1 Drug Resistance Development Through Week 48 in Antiretroviral Naive Subjects on Rilpivirine/Emtricitabine/Tenofovir DF or Efavirenz/Emtricitabine/Tenofovir DF in the STaR Study (GS-US-264-0110)
Porter, Danielle P.
Kulkarni, Rima
Fralich, Todd
Miller, Michael D.
White, Kirsten L.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 65 (03) : 318 - 326
[8] STaR Study: Single tablet regimen rilpivirine/emtricitabine/tenofovir DF is non-inferior to efavirenz/emtricitabine/tenofovir DF in ART-naive adults regardless of baseline viral load and CD4+count
Wilkins, E.
Cohen, C.
Wohl, D.
Arribas, J.
Henry, K.
Van Lunzen, J.
Bloch, M.
Towner, W.
Wang, H.
Porter, D.
De-Oertel, S.
Aizen, K.
Fralich, T.
HIV MEDICINE, 2013, 14 : 55 - 55
[9] Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects
Allavena, C.
Dailly, E.
Reliquet, V.
Bonnet, B.
Pineau, S.
Andre-Garnier, E.
Boutoille, D.
Bouquie, R.
Raveleau, A.
Bouchez, S.
Billaud, E.
Raffi, F.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (10) : 2804 - 2808
[10] SPIRIT: switching to emtricitabine/rilpivirine/tenofovir DF single-tablet regimen from boosted protease inhibitor maintains HIV suppression at week 48
Fisher, M.
Palella, F.
Tebas, P.
Gazzard, B.
Ruane, P.
van Lunzen, J.
Shamblaw, D.
Flamm, J.
Ebrahimi, R.
White, K.
Guyer, W.
Porter, D.
Fralich, T.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 157 - 158

← 1 2 3 4 5 →